The Week in Review: April 28 – May 11, 2018

Friday, May 11, 2018 News Recap: HBV: CADTH recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B. The CADTH Canadian Drug Expert Committee (CDEC) recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B in adults with compensated liver disease, if the following condition is met: CONDITION: The drug plan cost of TAF should not exceed that of the lowest-cost prepar...

Er Nurse Could Have Exposed Thousands of Patients to Hepatitis C Infection, Officials Warn

Officials are urging thousands of patients treated at a hospital in the State of Washington to get tested for Hepatitis C, amid fears two patients contracted the disease from a nurse working in the emergency department. The MultiCare Good Samaritan Hospital in Puyallup, Washington, warned in a safety alert statement that patients who were treated at the ER between August 4, 2017 and March 23, 2018 could have been exposed to the disease. The hospital is

The Week in Review: July 14 – July 21, 2017

Friday, July 21, 2017 News Recap 1) Vosevi Approved in US – Under Review in Canada Vosevi has just been approved in the USA to treat adults with chronic HCV genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing sofosbuvir, velpatasvir and a new drug, voxilaprevir. Vosevi is the first treatment approved for patients who have been previously treated with DAAs and failed treatment....

Hepatitis C outbreak spurs closer monitoring of Utah health professionals

The hepatitis C outbreak at two Northern Utah hospitals, attributed to a nurse accused of diverting drugs and infecting at least 7 patients, has spurred the state to increase monitoring of health care professionals. The Utah Department of Health has begun working more closely with licensing authorities “to understand when a provider is potentially exposing patients to blood-borne pathogens due to risky behaviors,” said Dr. Angela Dunn, deputy state epidem